Pfizer has acquired a 15% equity interest in privately held biotech company Vivet Therapeutics for €45 million and secured an exclusive option to buy all outstanding shares.
- Pfizer & Vivet will collaborate on development of VTX-801 treatment for Wilson disease
- Pfizer may pay up to €560 million inclusive of option exercise payment & subject to certain milestones
- Option to buy 100% can be exercised following delivery of data from Phase I/II clinical trial for VTX-801
- Monika Vnuk, Pfizer VP, Worldwide Development, will join Vivet’s Board of Directors
Link to Statement: Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet...